The Mucopolysaccharidoses: A Synergism between Clinical and Basic Investigation  by Fluharty, Arvan L.
0022-Z02X/H2/790:1-0O:J8s$02.00/0 
THE .JOORNAL OF INVESTIGATIVE DERMATOLOGY, 79::18s-448, 1982 
Copyright © 1982 by The Williams & Wilkins Co. 
Vol. 79, Supplement 1 
Printed in U.S.A. 
The Mucopolysaccharidoses: A Synergism between Clinical and Basic 
Investigation 
ARVAN L. FLUHARTY, PH,D, 
MRRC-UCLA Research Group, Lanterman State Hospital, Pomona, California, U.S.A. 
The mucopolysaccharidoses are a family of genetic 
diseases involving faulty degradation of one or more 
type of mucopolysaccharide or glycosaminoglycan. 
These conditions are characterized by skeletal, connec­
tive tissue, and intellectual manifestations. Biochemical 
investigations over the past 10-20 yr have enhanced our 
understanding of the clinical conditions and advanced 
our knowledge of catabolic pathways for complex bio­
logical structures. 
Identification of stored and excreted materials as par­
tially degraded glycosaminoglycans allowed classifica­
tion of these conditions on clinical and chemical criteria. 
The development of a cell culture model for studying the 
mucopolysaccharidoses lead to the identification of a 
variety of lysosomal sulfatases and glycosidases as de­
ficient enzymes. This stimulated the identification of 
several new conditions. Knowledge of primary biochem­
ical defects improved genetic services by providing ac­
curate diagnosis, facilitating carrier identification and 
improving prenatal diagnosis. 
Glycosaminoglycan excretion patterns associated with 
individual enzyme defects suggested sequential degra­
dative pathways for GAGs and related macromolecules. 
Attempts at enzyme replacement revealed a complex 
system of recognition markers and membrane receptors 
for the uptake of extracellular proteins. Multiple enzyme 
deficiencies are providing information on lysosomal en­
zyme synthesis and processing. The mucopolysaccharide 
storage diseases offer an excellent example of a produc­
tive synergism between basic biology and clinical medi­
cine. 
We usually think of the link between basic sciences and 
clinical medicine as one where basic information derived from 
microbial and animal studies is eventually applied to a clinical 
condition. Occasionally the flow of information is in the reverse 
direction such that consideration of a clinical situation provides 
insight into some basic biological process. This has been the 
case with the mucopolysaccharidoses where attempts to under­
stand the biochemical bases of a group of human genetic 
diseases has defined the details of a major catabolic pathway. 
In addition an unexpected mechanism for the incorporation of 
enzymes into subcellular organelles has been revealed. More 
correctly the scientific and medical advances have operated in 
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Abbreviations: 
AR: autosomal recessive 
C4S, CSA: chondroitin-4-sulfate or chondroitin sulfate A 
C6S, CSC: chondroitin-6-sulfate or chondroitin sulfate C 
DS, CSB: dermatan sulfate or chondroitin sulfate B 
GAG: glycosaminoglycan 
HA: hyaluronic acid 
Hep: heparin 
HS: heparan sulfate 
KS: keratan sulfate 
MPS: mucopolysaccharidosis 
a synergistic manner as each domain has fed back information 
of value to the other. 
The mucopolysaccharidoses (MPS) are conditions in which 
there is an excessive accumulation of acidic polysaccharides in 
tissues, usually accompanied by their enhanced urinary excre­
tion. These polysaccharides, which owe their acid character to 
a high uronic acid content and/or sulfate ester substituents, 
were referred to in the past as mucopolysaccharides. The pres­
ently preferred nomenclature is glycosaminoglycan or GAG, 
Mucopolysaccharidoses is still utilized in describing the clinical 
entity since it is well established in the medical literature and 
the logical substitution, glycosaminoglycanosis, seems unduly 
burdensome. As presently conceived the MPS are genetic de­
fects of the lysosomal catabolic system. They constitute a part 
of a larger class of disorders, the lysosomal storage diseases. 
While the MPS can encompass a variety of clinical presenta­
tions, there is a classic constellation of suggestive features. 
Patients are generally normal at birth, but over a period of 
months to years develop a "Hurler" look: short stature, coarse 
features, frontal bossing, thickened skin, thick and abundant 
hair, herniation, chronic rhinitus, and characteristic bone de­
formities. Corneal clouding, severe skeletal malformations, car­
diac lesions, and mental retardation accompany some MPS 
types but are absent in others. The critical laboratory finding 
is an elevated GAG level in the urine. The class of GAG 
excreted helps in making the differentiation between MPS 
types. A number of excellent reviews of the MPS are available 
and can be consulted for details [1-4]. A summary of the clinical 
subtypes of the MPS is presented in Table I. 
The typical MPS appearance has been likened to the gar­
goyles adorning European cathedrals [5], leading to a wide 
spread use of the term gargoylism to describe this group of 
disorders. While most professionals decry the use of this un­
flattering term, its graphic impact and the complexity of terms 
such as mucopolysaccharidoses and glycoaminoglycan probably 
accounts for its amazing persistence. 
The MPS are comparatively rare conditions with the occur­
rence of a given subtype usually cited as around 1 in 10", making 
the overall incidence somewhere in the range of 1 in 104 births 
with roughly 1 in 100 individuals being an MPS carrier. There 
is no notable predilection for any population. 
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GAG STRUCTURE 
In order to discuss the biochemistry of the MPS some ac­
quaintance with the chemical make-up of the GAG is necessary. 
A GAG is a repeating linear sequence of a type-specific disac­
charide (Fig 1). Most often the disaccharide consists of a uronic 
acid and a N -acetylhexosamine and is repeated 20-50 times in 
the typical GAG chain. One or more sulfate residues per dimer 
unit are present in most types. Variation within this basic 
scheme provides the 6 GAG types found in animal tissues. The 
amino sugar may be either glucosamine or galactosamine, its 
linkage may be either IX or f3 to either the 3 or 4 hydroxyl of the 
adjacent sugar residue, it may have been a N-acetyl or N­
sulfuryl substituent, and it may be sulfated on the 4 hydroxyl, 
the 6 hydroxyl, or both. The second sugar can be glucuronic 
acid, iduronic acid or galactose. The latter 2 may carry sulfate 
substi:llents on the 2 or the 6 position respectively. Mixed types 
are not usually encountered although regions of chondroitin 
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TABLE I. Clinical Classification of the MP8 
Comments Designation Urinary Genetics Key Features GAG Syndrome 
Hurler MPS I, MPS IH DS,HS AR Mental retardation, skeletal de-
formities, heart defects, cor-
neal opacity, hepatospleno-
megaly 
Hunter MPS II DS,HS X-linked Moderate mental retardation, Milder allelic form 
Sanfilippo 
Morquio 
Scheie 
Maroteaux-Lamy 
,B-glucuronidase defi­
ciency 
N -acetylglucosamine 
6 sulfatase defi­
ciency 
MPS III 
MPS IV 
MPS V, MPS IS 
MPSVI 
MPS VII 
MPS VIII 
HS AR 
KS AR 
DS,HS AR 
DS AR 
DS,HS AR 
KS (HS?) AR? 
sulfate and derma tan sulfate structure do occur in the same 
chain. Both iduronic and glucuronic residues occur concurrently 
in heparin and heparan sulfate sequences as do both N-acety­
lated and N -sulfated glucosamines. Sulfation can be somewhat 
variable with both over and undersulfated examples reasonably 
common. 
Two classes of GAG can be differentiated on the basis of 
susceptibility to breakdown by mammalian hyaluronidase; hy­
aluronic acid (HAl. chondroitin 4 sulfate (C4S) and chondroitin 
6-sulfate (C6S) are cleaved while dermatan sulfate (DS), kera­
tan sulfate (KS) and heparin/heparan sulfate (Hep/HS) are 
resistant. It is the latter group which accumulate in and are 
excreted by MPS patients. 
Most GAG elements do not exist in the body as such but are 
constituents of more complex structures [6]. A number of GAG 
chains, often of different types, are linked covalently to a 
common protein "core" making up a proteoglycan. This is 
conceived as a "bottle brush" sort of structure with the highly 
charged polysaccharide chains tending to repel each other. A 
portion of the protein core may be embedded in the exterior of 
the cell wall or non covalently linked to hyaluronic acid. A large 
number of proteoglycans can interact with a given hyaluronic 
acid molecule resulting in an extended aggregation. These are 
the basic structural elements of the amorphous ground sub­
stance of connective tissue. Intermeshed through the protein 
polysaccharide matrix are fibrous elements such as collagen 
and elastin. GAG molecules accumulating in the tissues of MPS 
patients are smaller than those found in normal tissues and are 
pretty much devoid of protein. Thus they appear to be partial 
breakdown products of the complex extracellular matrix. 
The biological roles of the GAG are poorly defined. Their 
most dramatic property is the extremely large volume occupied 
by the hydrated molecules. They form highly viscous solutions 
and gel-like solids. This allows GAG containing molecules to 
act as biological lubricants and to stabilize the organization of 
fibrous and cellular elements of the tissue. GAG have ion­
exchange properties and may act as cation traps, modulating 
the immediate salt and nutrient environment of the cells. GAG 
seem to function primarily outside of cells although some 
intracellular roles cannot be excluded. The most avid devotees 
skeletal deformities, clear cor-
neas, hepatosplenomegaly 
Mental retardation, clear cor-
neas, mild skeletal involve-
ment, storage features de-
velop slowly 
Severe skeletal deformities, cor-
neal opacity , normal intelli-
gence 
Normal intelligence, mild bone 
and joint involvement, cor-
neal opacity 
Skeletal deformities, normal in-
telligence, corneal opacity, 
hepatosplenomegaly 
Variable clinical features , may 
include mental retardation, 
skeletal defects 
Similar to MPS IV with mental 
retardation 
4 enzymatically dis­
tinct subtypes 
A-I) 
2 or 3 possible en­
zyme subtypes 
Alellic with MPS I 
Milder allelic form 
Might be classified 
as a MPS I sub­
type 
Might be classified 
as a MPS IV sub­
type, status of 
one index case is 
unclear 
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FIG 1. Typical disaccharide repeating units for GAG. Also included 
are points of action for GAG degrading enzymes: T endoglycosidases, 
• exoglucosidases, • sulfatases, • other. The numbers refer to those 
indicated in Table III. 
would have the GAG directing cell growth, differentiation, 
repair and aging. The diversity of their biological influences can 
best be appreciated by noting the variety of consequences 
attendant on their faulty metabolism. Several excellent reviews 
of GAG and proteoglycan structure and function have recently 
appeared [e.g., 7,8]. 
HISTORY OF THE MPS 
For purposes of the medicine-biology synergism theme it is 
useful to divide the history of the MPS into 3 periods and to 
propose a fourth for the future. These are summarized in Table 
II. The first period, stretching from roughly 1900 to 1950, is that 
of Clinical Pathology. It is characterized by careful and detailed 
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TABLE II. Summary of MPS History 
-------
Clinical Pathology Period (1900-1950) 
Before 1920 Descriptions of the classic syndrome by Hunter and 
Hurler 
1920-1940 Use of Gargoylism, Dysostosis multiplex, Lipochod-
rodystropy 
1940's Differentiation of autosomal and X-linked forms 
Chemical Pathology Period (1950-1970) 
1952-1958 GAG excretion and storage demonstrated 
1955-1965 Recognition of lysosomes and lysosomal storage dis-
eases 
1965 McKussic classification of MPS 
1965 Introduction of tissue culture model for MPS 
1965-1970 Showing GAG breakdown defect-corrective factors 
Enzyme Pathology Period (1970-1980) 
1972 Iduronidase defect in MPS I and V established 
1972-1980 MPS enzyme defects elucidated 
Rational Therapy Period (l980-?) 
Speculative Enzyme replacement, Gene replacement 
case descriptions and attempts to organize these into useful and 
rational categories. Possibly the most notable landmarks were: 
the clinical descriptions by Hunter in 1917 [9] and Hurler in 
1919 [10] delineating the prototype syndrome, the introduction 
of the term gargoylism which sticks so tenaciously to this class 
of defects despite gallant efforts to discourage its use, the 
incorrect recognition of the stored material as primarily lipoidal 
leading to the MPS being indexed for many years under the 
classification of lipochondrodystrophy by Index Medicus, and 
the recognition in the 1940's of distinct autosomal and x-linked 
forms [11]. The importance of this Clinical Pathology Period 
for subsequent biochemical developments can not be over­
stressed. 
The second period, that of Chemical Pathology, occurred 
between 1950 and 1970 beginning with Brante's isolation and 
identification of stored GAG (mucopolysaccharide at this time) 
from a MPS patient and the introduction of the term mucopol­
ysaccharidosis [12]. Basic scientific work by Meyer [13] and 
others on the isolation and characterization of GAG was rapidly 
applied to refming MPS diagnoses on chemical grounds . The 
recognition of MPS subforms with distinct storage and excre­
tion patterns followed. A major contribution was made by 
McKusick's laboratory who proposed a systematic classification 
of the MPS using both numerical and eponymic designators 
[14]. Modifications of this scheme (cf., Table I) underlie almost 
all subsequent discussions of the MPS. The last part of the 
Chemical Pathology Period is dominated by the finding that a 
characteristic pathologic manifestation, the accumulation of 
metachromatically staining material (GAG), could be demon­
strated in cultures of skin fibroblasts derived from MPS patients 
[15,16]. Exploitation of cell culture techniques by Neufeld's 
group [17] and others set the stage for discovery of the enzyme 
defects with its harvest of both clinical and biological advances. 
Also notable during this period are: the discovery of the lyso­
some, the conceptualization of lysosomal storage diseases, the 
demonstration that the MPS are members of this class [18], 
and the shift in emphasis from the isolated GAG to their 
occurren(:e as more complex proteoglycans and higher order 
structures [6]. 
The period of Enzyme Pathology spans the past decade. The 
lysosomal storage disease postulate predicted that each syn­
drome would result from a deficiency of a lysosomal hydrolase, 
and the first such defect in an MPS was defined in 1972 
[19,20]. Enzyme deficits for each of the MPS have now been 
established, and some previously unknown lysosomal enzymes 
have been discovered. 
We can anticipate a fourth period in the history of the MPS, 
that of Rational Therapy. This is, of course, the ultimate 
objective of both physicians and basic scientists investigating 
any biomedical problem. In the case of the MPS an appropriate 
stage has now been set, and perhaps in the 1980's we will see 
this goal achieved. 
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ENZYMES OF GAG CATABOLISM 
What then are the enzyme systems responsible for GAG 
breakdown and how do they account for the MPS excretion 
patterns. Several strategies for the breakdown of these linear 
polymers can be envisioned. Random endolytic scission with 
the eventual production of monomers and small oligomers could 
occur. Alternately, structural elements might be released se­
quentially from either end. Complete sulfate removal might be 
necessary before glycosidic cleavage, it might occur indepen­
dently anywhere along the chain, or it might be a step in a 
sequential exolytic sequence. The nature of the accumulations 
in the MPS imply an obligate sequential exolytic pathway for 
at least some types of GAG. Desulfation must be a part of the 
obligatory sequence since stored GAG are highly sulfated. An 
alternate endolytic pathway must also exist for other GAG 
since they do not accumulate even though they contain some 
of the same linkages as the storage products. Since these are 
the same GAG which are susceptible to testicular hyaluroni­
dase, the action of hyaluronidase-like endoglycosidoses in other 
mammalian tissues can be surmized. Some limited endolytic 
action on KS, DS, and HS is also likely since the materials 
accumulating in the MPS are smaller than present in normal 
tissues. Some disaggregation of large ground substance proteo­
glycan complexes must occur extracellularly, but the lysosomal 
nature of the MPS deposits implies that ultimate GAG catab­
olism occurs within cells. Protein and polysaccharide break­
down appear not to be interdependent and only a few amino 
acids from protein linkage regions remain attached to the GAG 
chains. 
Detailed exolytic pathways for the GAG can be inferred with 
almost every known linkage now represented by an enzyme 
deficiency syndrome. The positions of enzyme action are indi­
cated on Fig 1 and listed in Table III. The a-iduronidase 
deficiency in the Hurler syndrome (MPS-I) was the first to be 
established [19,20]. The same enzyme is also absent in the 
Scheie syndrome (MPS-V) now recognized as an allotypic 
variant of MPS-I [20]. Iduronic acid residues occur in both DS 
and Hep/HS explaining their accumulation in these conditions. 
Iduronic acid residues can be sulfated in both polymers, more 
often in Hep/HS than DS. The absence of iduronate sulfate 
sulfatase in Hunter syndrome (MPS-II) [21,22] therefore results 
in the same GAG accumulation profile and similar clinical 
manifestations to those in MPS-I. 
Certain linkages are unique to the Hep/HS group of polymers 
TABLE III. Enzymes of GA G Catabolism 
Enzyme GAG Cleaved MPS Defect Symbol Fig 1 
Endoglycosidases W Hyaluronidase HA,C4S, C6S 
Exoglycosidases 
,B-Glucuronidase HA, C4S, MPS VII CD 
C6S, Hep/ 
HS 
a-Iduronidase DS, Hep/HS MPSI, MPS ® 
V 
,B-Galactosidase KS MPS IVB � a-N-Acetylhexosamini- Hep/HS MPS IIIB 
dase 
,B-N-Acetylhexosamini- HA, C4S, ® 
dase C6S,KS, 
DS 
Sulfatases 
Arylsulfatase B C4S,DS, MPS VI [] 
Iduronate 2S Sulfatase DS, Hep/HS MPS II I2l 
Heparin Sulfamidase Hep/HS MPS IlIA [a] 
Gal/GaINAc6S Sulfatase C6S, KS MPS IVA 14l 
GlcNAc6S Sulfatase K KS MPSIVC lID 
GlcNAc6S Sulfatase H Hep/HS MPS I1ID !ffi 
Other 
Acetyl Transferase Hep/HS MPS I1IC ¢ 
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and deficiencies in any of the enzymes responsible for their 
hydrolysis produce the Sanfilippo syndrome (MPS-III). Hepa­
rin sulfate sulfamidase releases the amino group sulfate located 
on a terminal residue in the polymer. It is absent in what has 
been designated the type A Sanfilippo syndrome (MPS-IIIA) 
[23]. The resulting aminosugar end group cannot be removed 
until the free amino group is acetylated. This is accomplished 
by transfer of an acetyl group from acetyl CoA by a lysosomal 
acetyl transferase. The absence of this enzyme is responsible 
for the C type Sanfilippo syndrome (MPS-IIIC) [24]. Removal 
of the terminal linked N-acetylglucosamine requires an a-N­
acetylhexosaminidase and this enzyme is missing in the B type 
Sanfilippo syndrome (MPS-IIIB) [25]. Evidence has recently 
been presented for a Hep/HS specific N-acetylglucosamine-6-
sulfate sulfatase differing from that acting on this structure in 
KS. It is designated herein as the H type enzyme, and its 
deficiency accounts for an additional type of Sanfilippo syn­
drome (MPS-IIID) [26]). 
Morquio syndrome (MPS-IV) is characterized by the accu­
mulation of KS and results from the deficiency of a sulfatase 
specific for the 6 position of sugars with the galacto-configura­
tion [27]. This enzyme is usually referred to as N-acetylgalac­
tosamine-6-sulfate sulfatase since this is the structure of the 
assay substrate derived from C6S. However, it is the galactose-
6-sulfate linkage of KS which is susceptible to this enzyme. A 
N-acetylglucosamine-6-sulfate sulfatase is also required for KS 
degradation, and as noted above this enzyme is probably not 
the same as that acting on Hep/HS [26]. Deficiency of this 
enzyme would best be described as a Morquio syndrome sub­
type by analogy to the MPS-III situation although MPS-VIII 
has also been suggested. (It should be noted that the diagnostic 
status of one of two reported patients with this defect is in 
question [26,27]). The absence of the predominant lysosomal 
f3-galactosidase also results in the accumulation of KS. In its 
commonest manifestation this enzyme defect also results in 
ganglioside accumulation and is designated GMI gangliosidosis 
[29]. There are some patients in which the MPS symptoms 
seem to dominate and these patients can be considered as 
belonging to a MPS-IV subtype [30,31]' 
Arylsulfatase B, which appears to function physiologically as 
an N-acetylgalactosamine-4-sulfate sulfatase is deficient in the 
Maroteaux-Lamy syndrome (MPS-VI) [32]. This linkage is 
found only in DS among the GAGs with obligate sequential 
pathways, but the enzyme can be assayed with appropriate C4S 
fragments. A MPS due to a deficiency in f3-glucuronidase has 
also been described [33]. The clinical situation and GAG excre­
tion patterns accompanying this defect are quite variable. It 
has been designated MPS-VII without any associated eponym. 
It might reasonably be considered a non-allelic subform of 
MPS-I. 
The only GAG linkages not accounted for are the f3-linked 
N-acetylhexosamines. While there is mounting evidence that 
N-acetylhexosaminidase A and B can cleave these GAG bonds, 
no GAG accumulation occurs in either Tay-Sachs or Sandhoff 
diseases which are the f3-N-acetylhexosaminidase deficiency 
syndromes. Perhaps additional GAG specific f3-N-acetylhexo­
saminidases occur in mammalian tissues providing optional 
ways to cleave this residue. If so, this step is unlike all of the 
others in the GAG catabolic process. 
BIOLOGICAL IMPACT OF ENZYME PATHOLOGY 
The greatest contribution to basic biology deriving from the 
elucidation of the MPS enzyme defects is that it defines in 
detail the end-stage pathways for GAG catabolism. The oblig­
atory nature of these pathways, with set sequences for removal 
of sulfate and saccharidic components, was not anticipated from 
studies on non-human systems. Many of the enzymes involved 
were first detected in the human investigations. Some steps 
such as N-acetylation in the Hep/HS pathway were not even 
postulated. 
When one combines information on the chemical nature of 
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stored and excreted GAG, the structure of proteoglycans, the 
mechanism of proteoglycan aggregation, and the specificity of 
hyaluronidase-type enzymes one can postulate a general 
scheme for proteoglycan catabolism. The initial steps must be 
assumed to occur in the extracellular environment. Endolytic 
proteases and glycosidases initiate a disaggregation of the or­
ganized structures. The resulting macromolecular fragments 
are taken up into the lysosomal compartment of adjacent cells. 
Lysosomal proteases complete the cleavage of protein segments 
linking GAG chains and endoglycosidases fragment susceptible 
chains to a size where the exolytic processes become dominant. 
The final stage is the sequential removal of individual end­
group elements. The general pathway is summarized in Fig 2 
and the sequential exolytic scheme for Hep/HS is detailed in 
Fig 3. The GAG are thus reduced to their monomeric constit­
uents or to residual segments small enough to be lost from the 
cell and eventually excreted. It is the final process which fails 
in the MPS and GAG containing structures dependent on the 
exolytic systems accumulate. 
Just how GAG accumulations lead to the clinical symptoms 
seen in the MPS is not clear. Cell death, particularly in the 
nervous system, from accumulated debris must account for 
much of the end-stage pathology. An effect of residual GAG 
fragments on other lysosomal enzymes and on the cells inter­
pretation of developmental signals has some experimental sup­
port [34]. This is an area where future contributions of MPS 
studies to general biology can be anticipated. 
CLINICAL VALUE OF ENZYME PATHOLOGY 
What is the impact of enzyme defect information on the 
clinical management of the MPS? First it provides a method 
for reliable diagnosis, permitting more accurate prognosis and 
enhancing the value of genetic counseling. For example, it is 
now possible to rapidly make the important differentiation 
between X-linked and autosomal forms. Knowledge of the 
genetic complexity of the Sanfilippo syndrome and the allelism 
of the Hurler-Scheie complex alters the type of information 
provided to families. Some of the clinical variability in what 
appeared to be single disorders can now be understood. This is 
somewhat balanced by the realization that deficits in a given 
enzyme can result in diverse clinical presentations. The avail­
ability of stored tissue or cell cultures has permitted the diag-
F 
t 1. Break up of complex structures {proteolysis?} 
�.o. 
+ 2. Fragmentation {endolytic enzymes} 
• 
3. Sequential processing 
{exolytic enzymes} 
FIG 2. Generalized breakdown pathway for proteogiycan GAG. 
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SEQUENTIAL Hep/HS BREAKDOWN 
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FIG 3. 
nosis of deceased individuals which has resulted in revision of 
counseling in some instances. 
It should be noted that clinical application of information on 
specific enzyme defects in the MPS remains somewhat limited 
due to poor availability of the assays. Often the enzyme defects 
have been established with substrates generated by complex 
protocols such as that for iduronate sulfatase [35]. Few, if any, 
laboratories have the ability to assay all of these enzymes and 
even a partial capability is relatively rare. One very important 
area of current research is the development of better substrates 
and assay protocols which can be more widely utilized, 
[e.g., 36]. 
A second important clinical application of specific enzyme 
analysis is the identification of carriers. The presence of only a 
single functional gene results in a decreased activity for most 
lysosomal enzymes-a gene dose effect. Most established MPS 
carriers-parents of multiple affected patients-have below 
average activity of the enzyme in question in one or more type 
of reasonably available sample [37]. However, a considerable 
overlap between normal and carrier ranges is often encountered. 
This limits the potential for general screening programs such 
as that in effect for Tay-Sachs disease. Most workers do feel 
that enzymatic identification of heterozygote carriers within a 
limited family risk-group is feasible. 
Special mention should be made of the problem of carrier 
diagnosis for the X-linked Hunter syndrome (MPS-II). Unlike 
the situation with the autosomal recessive forms, the risk of an 
affected child is quite high for a carrier female irrespective of 
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her mate. Identifying the status of close female relatives of 
MPS II patients is therefore critical. The concept that one X­
chromosome becomes inactivated-the Lyon hypothesis­
leads to the prediction that a carrier would in effect be a mosaic 
of deficient and normal cell types. Carrier status should be 
ascertainable by enzymatic evaluation of cell clones. This has 
been confirmed by studies on carefully cloned fibroblasts [38], 
but this approach is far too difficult for routine application. 
Fortunately the enzyme, iduronate sulfate sulfatase, is amaz­
ingly stable and can be assayed at very high sensitivity. Its 
measurement in single hair roots has led to studies on exploiting 
the "quasi-cloned" nature such samples for MPS-II carrier 
diagnosis [39,40]. Promising results have been obtained. At 
present there is some uncertainty about the predictive useful­
ness of this approach and additional investigation is needed. 
The third important clinical application of enzyme defect 
information has been in prenatal diagnosis. Prenatal tests for 
the MPS based on radioactive GAG accumulation were suc­
cessfully carried out before the enzyme defects were elucidated, 
but the potential for non-specific effects was always present. 
Specific enzyme determination such as we were able to employ 
for the Maroteaux-Lamy syndrome (MPS-VI) provides more 
selectivity and certainty [41]. However, the behavior of enzymes 
in developing tissue and early amniotic fluid cell cultures has 
not been adequately studied and the ability to apply both 
enzymatic and cell loading criteria has been reassuring. 
Perhaps the most promising application of enzyme defect 
information is in the design of rational treatment. The concept 
of lysosomal storage diseases includes the postulate that they 
would be particularly amenable to direct replacement [18]. Cell 
up-take by endocytosis would place lysosomal enzymes in the 
appropriate intracellular milieu. Neufeld's group demonstrated 
cross correction between cultured fibroblasts from patients with 
deficient MPS subtypes and subsequently refined several pro­
tein corrective factors [17]. The eventual demonstration that 
corrective factors were forms of the missing enzymes estab­
lished the feasibility of enzyme replacement for the MPS, at 
least within the framework of the tissue culture model. At­
tempts to extend this concept to MPS patients have so far been 
of limited value [42]. Problems have involved obtaining appro­
priate amounts of adequately pure enzyme for human admin­
istration and insuring that it is delivered to and assimilated by 
the most involved tissues. Perhaps the most promising results 
have been obtained in attempts to colonize the patient with 
competent fibroblasts [43] so as to provide an internal supply 
of enzyme over an extended period. The long term value of this 
approach has yet to be evaluated. 
Another difficulty in developing replacement therapies for 
the MPS has been a paucity of relevant animal models. Re­
cently reported MPS cats with established enzyme defects 
should facilitate therapeutic investigations when they become 
generally available [44,45]. The advent of mammalian gene 
cloning and applied genetic engineering holds promise for more 
available replacement enzymes and for actual gene replace­
ment, at least at the somatic cell level. 
ENZYME UPTAKE MECHANISMS 
Studies on enzyme replacement in MPS cell cultures has led 
to basic information on cellular protein uptake mechanisms. 
This in turn has stimulated research on the processing of 
lysosomal enzymes within cells. Iduronidase added to culture 
media was taken up by MPS-I fibroblasts more efficiently than 
could be accounted for by simple pinocytosis [20]. This sug­
gested the presence of some sort of specific uptake mechanism. 
,B-Glucuronidase from some sources was efficiently assimilated 
while that from others was not [46]. This implicated an uptake 
recognition marker not related to the enzymes catalytic activity. 
This marker has recently been associated with an oligosaccha­
ride adduct. All lysosomal enzymes appear to be glycoproteins 
and their uptake by cultured fibroblasts seems to depend on 
the presence of mannose phosphate terminated oligosaccha-
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rides [47]. This structure promotes an interaction of the enzyme 
with a specific membrane binding protein and the complex 
becomes internalized in an energy dependent process [48]. The 
phosphorylation of the oligosaccharide mannose has recently 
been shown to involve a transfer of a I-phosphoryl N-acetyl­
galactosamine from UDP-N-acetylgalactosamine to form a 
phospho diester intermediate [49]. Loss of the N -acetylgalacto­
samine then generates the active uptake form. Removal of the 
phosphate residue results in the loss of capacity for carrier 
mediated uptake by fibroblasts. An excretion-uptake mecha­
nism based on this recognition system has been proposed to 
account for the localization of enzymes within the lysosome. 
While actual excretion is no longer considered a necessary step 
in lysosomal enzyme packaging, some topological equivalent 
involving the mannose phosphate recognition system is thought 
to be involved. [48]. 
. 
MULTIPLE ENZYME DEFECTS 
Failure of the lysosomal enzyme processing and localization 
mechanisms has provided an explanation for an unusual class 
of multi-enzyme defects related to the MPS [50]. These pres­
ently fall under the classification of mucolipidoses and are 
commonly referred to as I-cell (ML-II) or pseudo Hurler disease 
(ML-III). A clinical picture resembling the MPS is encountered 
without GAG excretion. Several lysosomal enzymes are ele­
"ated in body fluids, but are deficient in cultured fibroblasts. 
Since most of the missing enzymes can be recovered from the 
culture media a failure in subcellular localization accompanied 
by loss from the cell is suggested. Incorporation and retention 
of normal high uptake forms of the lysosomal enzymes is 
unimpaired in I-cell fibroblasts. On the other hand enzymes 
from I-cell media do not readily enter deficient MPS cells. They 
do not appear to have appropriate mannose phosphate recog­
nition markers, with a deficiency in the UDP-N-acetylgalacto­
,amine transferase being implicated [49]. 
There is another multiple enzyme deficiency condition re­
lated to the MPS. Multiple sulfatase deficiency disease 
I MSDD) is often initially diagnosed as an MPS since there is 
:, urinary excretion of GAG resembling that in MPS-III [51]. 
( )n enzyme analysis all of the lysosomal sulfatases are found to 
I le deficient in most tissues. Defects in the genes for primary 
('nzyme structures seems unlikely on the basis of fibroblast 
I'nzyme studies and cell fusion experiments. No satisfactory 
('xplanation for this condition can be offered at the present 
1 ime. The involvement of a microsomal sulfatase with a role in 
.;teroid metabolism makes a simple lysosomal enzyme process­
; ng defect unlikely. Further study of this MPS related condition 
"'ill undoubtedly contribute to our basic biological knowledge 
:[bout the relationship between sulfatases. 
I would like to acknowledge the collaboration and leadership of Dr. 
t !ayato Kihara in our contributions to the MPS story. 
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